Recent Press Releases

Aetna Recognized by National Comprehensive Cancer Network for Evidence-Based Approach to Cancer Care

-- First national health plan to receive recognition -- HARTFORD, Conn.--(BUSINESS WIRE)-- The National Comprehensive Cancer Network® (NCCN) has praised Aetna (NYSE: AET) for its evidence-based

Lundbeck : expands its commercial opportunities in Canada and Latin America

Lundbeck is granted commercial rights to several Cephalon products in Canada and/or Latin America Treanda® (bendamustine hydrochloride) for Injection, Nuvigil® (armodafinil) Tablets [C-IV]

New Study: Proposals in Canada-EU trade negotiations would add $2.8 billion annually to Canada's prescription drug bill

Toronto, February 7, 2011 - Changes to Canada's drug patent system proposed by the European Union (EU) would add nearly $3-billion annually to Canada's prescription drug bill according to a new study

Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer

Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer -- Avastin Study in Recurrent, Platinum-Sensitive Ovarian Cancer Showed Women Lived Significantly Longer Without

Intellipharmaceutics Expands Drug Commercialization Expertise

TORONTO, Feb 7, 2011 (GlobeNewswire via COMTEX) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI | PowerRating) (TSX: I | PowerRating) today announced it has retained the services of Doll

Lotus Pharmaceuticals to add two additional stories to new headquarters

Lotus Pharmaceuticals, Inc., a pharmaceutical company, has announced that it will add two additional stories to its new headquarters building in Chaoyang District, Beijing, which is currently under

Dalton and Oncovir Enter Into a Manufacturing Services Agreement

TORONTO, Feb. 3, 2011 /PRNewswire/ -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered

Targacept to Present at 13th Annual BIO CEO & Investor Conference

WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that J. Donald deBethizy, Ph.D.,

Burn Therapy: A Regenerative Medicine Approach

It has been likened to an overfed starfish. In reality, however, what may look like just a yellow plastic thing is actually a bioreactor-a 3-dimensional breeding ground for cells-which much improves

Consumer Reports Health: Best Drugs for What Ails You, Plus Where to Buy Them for $4 a Month

Consumers still asking for pricey brand name drugs when equally effective, and sometimes safer, options are available for a fraction of the price YONKERS, N.Y., Feb. 8, 2011 /PRNewswire-USNewswire/

Teva Reports Full Year and Fourth Quarter 2010 Results

-- Record 2010 Sales Total $16.1 Billion, with Non-GAAP EPS of $4.54 -- -- Fourth Quarter Sales Total $4.4 Billion, with Non-GAAP EPS of $1.25 -- JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical

Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer

-- Avastin Study in Recurrent, Platinum-Sensitive Ovarian Cancer Showed Women Lived Significantly Longer Without Their Disease Getting Worse -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

Exelixis Announces February 14 Webcast of Presentation at the BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael Morrissey, Ph.D., the company’s president and chief executive officer, will present at the

American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP 15 mM/5 mL Phosphorus; 22 mEq/5 mL

American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium 5 mL Single Dose Vial, Lot# 0048 Due to Translucent Visible

Abbott's Ibis Technology Identified Fatal Disease Organism in Afghanistan

WASHINGTON, Feb. 7, 2011 /PRNewswire/ -- Today, at the American Society for Microbiology Conference on Biodefense and Emerging Diseases, scientists from Abbott Molecular presented data showing the

Teva Invites Public to Listen to Its 2011 Investor Meeting Webcast

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) invites investors and the general public to listen to a live audio webcast of its 2011 Investor Meeting on Wednesday,

Pfizer To Acquire Ferrosan's Consumer Healthcare Business

Builds on Pfizer's Strength in Dietary Supplements; Expands the Portfolio with New Products and New Markets NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has entered into

FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to Include Data Supporting the Recommended A

Study confirms appropriate dosing in pregnancy and postpartum PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration

For the Treatment of Moderate to Severe Psoriasis, the Highest Proportion of Surveyed Dermatologists and MCOs Indicate Tha

However, Nearly Half of Surveyed Dermatologists Chose Remicade as the Most Efficacious Therapy for Moderate to Severe Psoriasis, According to Findings from Decision Resources BURLINGTON, Mass.--(

FDA Approves Makena, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who

FDA Approves MakenaTM, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth St. Louis,